 | • レポートコード：MRC23Q36068 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、89ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のヒルシュスプルング病治療市場について調査・分析し、世界のヒルシュスプルング病治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（抗感染症薬、制吐剤、鎮痛剤）、用途別セグメント分析（病院、薬局、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Pfizer、Sanofi、Bayer Healthcare、Johnson and Johnson、Merck and Co.、Novartis AG、Bristol-Myers Squibb、Astellas Pharma、Abbott、Cipla Ltd.などが含まれています。世界のヒルシュスプルング病治療市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、ヒルシュスプルング病治療市場規模を推定する際に考慮しました。本レポートは、ヒルシュスプルング病治療の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、ヒルシュスプルング病治療に関するビジネス上の意思決定に役立てることを目的としています。 ・ヒルシュスプルング病治療市場の概要 - ヒルシュスプルング病治療のタイプ別セグメント - 世界のヒルシュスプルング病治療市場規模：タイプ別分析（抗感染症薬、制吐剤、鎮痛剤） - ヒルシュスプルング病治療の用途別セグメント - 世界のヒルシュスプルング病治療市場規模：用途別分析（病院、薬局、その他） - 世界のヒルシュスプルング病治療市場規模予測（2018年-2029年） ・ヒルシュスプルング病治療市場の成長トレンド - ヒルシュスプルング病治療の地域別市場規模（2018年-2029年） - ヒルシュスプルング病治療市場ダイナミクス - ヒルシュスプルング病治療の業界動向 - ヒルシュスプルング病治療市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：抗感染症薬、制吐剤、鎮痛剤 - 世界のヒルシュスプルング病治療のタイプ別市場規模（2018年-2023年） - 世界のヒルシュスプルング病治療のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、薬局、その他 - 世界のヒルシュスプルング病治療の用途別市場規模（2018年-2023年） - 世界のヒルシュスプルング病治療の用途別市場規模（2024年-2029年） ・ヒルシュスプルング病治療の地域別市場規模 - 北米のヒルシュスプルング病治療市場規模（2018年-2029年） - アメリカのヒルシュスプルング病治療市場規模（2018年-2029年） - ヨーロッパのヒルシュスプルング病治療市場規模（2018年-2029年） - アジア太平洋のヒルシュスプルング病治療市場規模（2018年-2029年） - 中国のヒルシュスプルング病治療市場規模（2018年-2029年） - 日本のヒルシュスプルング病治療市場規模（2018年-2029年） - 韓国のヒルシュスプルング病治療市場規模（2018年-2029年） - インドのヒルシュスプルング病治療市場規模（2018年-2029年） - オーストラリアのヒルシュスプルング病治療市場規模（2018年-2029年） - 中南米のヒルシュスプルング病治療市場規模（2018年-2029年） - 中東・アフリカのヒルシュスプルング病治療市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Pfizer、Sanofi、Bayer Healthcare、Johnson and Johnson、Merck and Co.、Novartis AG、Bristol-Myers Squibb、Astellas Pharma、Abbott、Cipla Ltd. ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Hirschsprung Disease Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Hirschsprung Disease Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Hirschsprung Disease Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Hirschsprung Disease Treatment in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Hirschsprung Disease Treatment include Pfizer, Sanofi, Bayer Healthcare, Johnson and Johnson, Merck and Co., Novartis AG, Bristol-Myers Squibb, Astellas Pharma and Abbott, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Hirschsprung Disease Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hirschsprung Disease Treatment.
The Hirschsprung Disease Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Hirschsprung Disease Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hirschsprung Disease Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Pfizer
Sanofi
Bayer Healthcare
Johnson and Johnson
Merck and Co.
Novartis AG
Bristol-Myers Squibb
Astellas Pharma
Abbott
Cipla Ltd.
Segment by Type
Anti-Infective Drugs
Antiemetic
Pain Reliever
Segment by Application
Hospital
Retail Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hirschsprung Disease Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hirschsprung Disease Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Anti-Infective Drugs
1.2.3 Antiemetic
1.2.4 Pain Reliever
1.3 Market by Application
1.3.1 Global Hirschsprung Disease Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hirschsprung Disease Treatment Market Perspective (2018-2029)
2.2 Hirschsprung Disease Treatment Growth Trends by Region
2.2.1 Global Hirschsprung Disease Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Hirschsprung Disease Treatment Historic Market Size by Region (2018-2023)
2.2.3 Hirschsprung Disease Treatment Forecasted Market Size by Region (2024-2029)
2.3 Hirschsprung Disease Treatment Market Dynamics
2.3.1 Hirschsprung Disease Treatment Industry Trends
2.3.2 Hirschsprung Disease Treatment Market Drivers
2.3.3 Hirschsprung Disease Treatment Market Challenges
2.3.4 Hirschsprung Disease Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hirschsprung Disease Treatment Players by Revenue
3.1.1 Global Top Hirschsprung Disease Treatment Players by Revenue (2018-2023)
3.1.2 Global Hirschsprung Disease Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Hirschsprung Disease Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hirschsprung Disease Treatment Revenue
3.4 Global Hirschsprung Disease Treatment Market Concentration Ratio
3.4.1 Global Hirschsprung Disease Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hirschsprung Disease Treatment Revenue in 2022
3.5 Hirschsprung Disease Treatment Key Players Head office and Area Served
3.6 Key Players Hirschsprung Disease Treatment Product Solution and Service
3.7 Date of Enter into Hirschsprung Disease Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hirschsprung Disease Treatment Breakdown Data by Type
4.1 Global Hirschsprung Disease Treatment Historic Market Size by Type (2018-2023)
4.2 Global Hirschsprung Disease Treatment Forecasted Market Size by Type (2024-2029)
5 Hirschsprung Disease Treatment Breakdown Data by Application
5.1 Global Hirschsprung Disease Treatment Historic Market Size by Application (2018-2023)
5.2 Global Hirschsprung Disease Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Hirschsprung Disease Treatment Market Size (2018-2029)
6.2 North America Hirschsprung Disease Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Hirschsprung Disease Treatment Market Size by Country (2018-2023)
6.4 North America Hirschsprung Disease Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hirschsprung Disease Treatment Market Size (2018-2029)
7.2 Europe Hirschsprung Disease Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Hirschsprung Disease Treatment Market Size by Country (2018-2023)
7.4 Europe Hirschsprung Disease Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hirschsprung Disease Treatment Market Size (2018-2029)
8.2 Asia-Pacific Hirschsprung Disease Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Hirschsprung Disease Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Hirschsprung Disease Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hirschsprung Disease Treatment Market Size (2018-2029)
9.2 Latin America Hirschsprung Disease Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Hirschsprung Disease Treatment Market Size by Country (2018-2023)
9.4 Latin America Hirschsprung Disease Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hirschsprung Disease Treatment Market Size (2018-2029)
10.2 Middle East & Africa Hirschsprung Disease Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Hirschsprung Disease Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Hirschsprung Disease Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Hirschsprung Disease Treatment Introduction
11.1.4 Pfizer Revenue in Hirschsprung Disease Treatment Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Detail
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Hirschsprung Disease Treatment Introduction
11.2.4 Sanofi Revenue in Hirschsprung Disease Treatment Business (2018-2023)
11.2.5 Sanofi Recent Development
11.3 Bayer Healthcare
11.3.1 Bayer Healthcare Company Detail
11.3.2 Bayer Healthcare Business Overview
11.3.3 Bayer Healthcare Hirschsprung Disease Treatment Introduction
11.3.4 Bayer Healthcare Revenue in Hirschsprung Disease Treatment Business (2018-2023)
11.3.5 Bayer Healthcare Recent Development
11.4 Johnson and Johnson
11.4.1 Johnson and Johnson Company Detail
11.4.2 Johnson and Johnson Business Overview
11.4.3 Johnson and Johnson Hirschsprung Disease Treatment Introduction
11.4.4 Johnson and Johnson Revenue in Hirschsprung Disease Treatment Business (2018-2023)
11.4.5 Johnson and Johnson Recent Development
11.5 Merck and Co.
11.5.1 Merck and Co. Company Detail
11.5.2 Merck and Co. Business Overview
11.5.3 Merck and Co. Hirschsprung Disease Treatment Introduction
11.5.4 Merck and Co. Revenue in Hirschsprung Disease Treatment Business (2018-2023)
11.5.5 Merck and Co. Recent Development
11.6 Novartis AG
11.6.1 Novartis AG Company Detail
11.6.2 Novartis AG Business Overview
11.6.3 Novartis AG Hirschsprung Disease Treatment Introduction
11.6.4 Novartis AG Revenue in Hirschsprung Disease Treatment Business (2018-2023)
11.6.5 Novartis AG Recent Development
11.7 Bristol-Myers Squibb
11.7.1 Bristol-Myers Squibb Company Detail
11.7.2 Bristol-Myers Squibb Business Overview
11.7.3 Bristol-Myers Squibb Hirschsprung Disease Treatment Introduction
11.7.4 Bristol-Myers Squibb Revenue in Hirschsprung Disease Treatment Business (2018-2023)
11.7.5 Bristol-Myers Squibb Recent Development
11.8 Astellas Pharma
11.8.1 Astellas Pharma Company Detail
11.8.2 Astellas Pharma Business Overview
11.8.3 Astellas Pharma Hirschsprung Disease Treatment Introduction
11.8.4 Astellas Pharma Revenue in Hirschsprung Disease Treatment Business (2018-2023)
11.8.5 Astellas Pharma Recent Development
11.9 Abbott
11.9.1 Abbott Company Detail
11.9.2 Abbott Business Overview
11.9.3 Abbott Hirschsprung Disease Treatment Introduction
11.9.4 Abbott Revenue in Hirschsprung Disease Treatment Business (2018-2023)
11.9.5 Abbott Recent Development
11.10 Cipla Ltd.
11.10.1 Cipla Ltd. Company Detail
11.10.2 Cipla Ltd. Business Overview
11.10.3 Cipla Ltd. Hirschsprung Disease Treatment Introduction
11.10.4 Cipla Ltd. Revenue in Hirschsprung Disease Treatment Business (2018-2023)
11.10.5 Cipla Ltd. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details